Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab Plus Ipilimumab in Aggressive Pituitary Tumors
NCT04042753Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jul 2019
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and ipilimumab in pituitary tumor and Pituitary carcinoma (PC), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Radiographic response rate at 36 weeks. Started Jul 2019; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
pituitary tumorPituitary carcinoma (PC)
Beyond the preview
Go deeper on NCT04042753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04042753.